HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cataract surgery and diabetes.

AbstractPURPOSE OF REVIEW:
Recent studies have focused on interventions to minimize progression of retinal disease in diabetic patients undergoing cataract surgery. Here, we review the evidence for progression of diabetic retinal disease with cataract surgery and critically analyze the interventions proposed to minimize it.
RECENT FINDINGS:
Peri-operative intravitreal bevacizumab, sub-Tenon's triamcinolone, and panretinal photocoagulation (PRP) after cataract surgery (instead of before) have been examined as ways to improve cataract surgery results in diabetic patients. The bevacizumab and triamcinolone results are promising, but the inclusion criteria are variable, the sample sizes are small, and the follow-up is short. Postsurgery PRP shows improved cataract surgery results in diabetics with more severe retinopathy up to 1 year after surgery.
SUMMARY:
Recent studies do not support the generalized conclusion that phacoemulsification surgery causes progression of retinopathy and macular edema in all diabetic patients. In certain populations of diabetic patients undergoing cataract surgery, peri-operative triamcinolone and bevacizumab may blunt the progression of diabetic macular edema and diabetic retinopathy. The optimal timing of PRP in relation to cataract surgery in patients with more severe retinopathy warrants further evaluation.
AuthorsAnkoor S Shah, Sherleen H Chen
JournalCurrent opinion in ophthalmology (Curr Opin Ophthalmol) Vol. 21 Issue 1 Pg. 4-9 (Jan 2010) ISSN: 1531-7021 [Electronic] United States
PMID19935423 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Triamcinolone Acetonide
Topics
  • Angiogenesis Inhibitors (administration & dosage)
  • Antibodies, Monoclonal (administration & dosage)
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Diabetic Retinopathy (etiology, physiopathology, prevention & control)
  • Disease Progression
  • Glucocorticoids (administration & dosage)
  • Humans
  • Laser Coagulation
  • Macular Edema (etiology, physiopathology, prevention & control)
  • Phacoemulsification
  • Triamcinolone Acetonide (administration & dosage)
  • Vascular Endothelial Growth Factor A (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: